← Back to front page
United States · Wires & real time · PR Newswire

Harbour BioMed Appoints Dr. Sanjay Keswani as Scientific Advisor in Neuroscience

Published by PR Newswire · United States 39 min ago
Harbour BioMed Appoints Dr. Sanjay Keswani as Scientific Advisor in Neuroscience
PR Newswire

Detailed summary

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to…

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Nov. 17, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. Sanjay Keswani as Scientific Advisor in Neuroscience.

Dr. Keswani brings over 25 years of experience in neuroscience research, pharmaceutical R&D and clinical development, spanning global pharmaceutical companies and biotechnology companies. His expertise encompasses neuroscience, neurodegenerative diseases, neuroimmunology, rare diseases and pain, with extensive experience in advancing innovative therapies from discovery through clinical development and regulatory approval.

Dr. Keswani most recently served as Chief Medical Officer of Neurocrine Biosciences, where he led clinical development across multiple therapeutic areas, including neurology, psychiatry, immunology, obesity and rare endocrine diseases. Prior to that, he served as President and CEO of ImmunoBrain, a clinical-stage biotechnology company focused on developing therapies that leverage neuro-immune communication to promote brain repair in patients with neurodegenerative diseases.

Dr. Keswani began his academic and clinical career at Johns Hopkins University, where he served as Assistant Professor of Neurology and conducted research in molecular neuroscience and neuroimmunology. Earlier in his career, he held senior R&D and clinical development positions at Bristol Myers Squibb, Eli Lilly and Amgen, contributing to the development of innovative therapies across neuroscience and other disease areas.

"We are delighted to welcome Dr. Keswani as our Scientific Advisor in Neuroscience," said Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed.

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.

Read the full article on PR Newswire Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.prnewswire.com)

Also worth reading